

ASX Announcement

6 December 2017

DIMERIX LIMITED NON-RENOUCEABLE ENTITLEMENT OFFER TO RAISE APPROXIMATELY \$5,524,906

Highlights

- One (1) for two (2) pro-rata non-renounceable entitlement offer at \$0.12 per share to raise approximately \$5,524,906.
- Commitments received from major shareholders, directors and management for at least \$800,000.
- Funds raised will be used to further the development plans for DMX-200 for both FSGS and diabetic nephropathy and for pre-clinical pipeline programs. For DMX-200 the funds will be used for commercial manufacture of both the pharmaceutical ingredient and the extended release tablet, regulatory activities, an FSGS phase 2 clinical trial, and formalisation of a development plan for diabetic nephropathy.
- Offer price of 12 cents (\$0.12) per new share, being a 31% discount to the 15-day VWAP to 30 November 2017.

Entitlement Offer

Dimerix Limited ACN 001 285 230 (**Dimerix** or **Company**) announces that it intends to undertake a 1 for 2 pro rata non-renounceable entitlement offer of fully paid ordinary shares in Dimerix (**New Shares**) to raise approximately \$5,524,906 (**Entitlement Offer**).

The offer price for the Entitlement Offer will be 12 cents per New Share (**Offer Price**). The Entitlement Offer Price represents a 31% discount to the 15 day VWAP to 30 November 2017 of Dimerix shares (the last trading day before this announcement).

Under the Entitlement Offer, eligible shareholders will be able to subscribe for one (1) New Share for every two (2) existing shares held at 7.00pm (AEDT) on 11 December 2017 (**Record Date**) at the Offer Price (**Entitlements**).

The Entitlement Offer is not underwritten however the Company has received commitments from major shareholders, directors and management to take up at least \$800,000 of their entitlements.

The funds raised from this Entitlement Offer will be used to further the development plans for DMX-200 for both FSGS and diabetic nephropathy and for pre-clinical pipeline programs. For DMX-200 the funds will be used for commercial manufacture of both the pharmaceutical ingredient and the extended release tablet, regulatory activities, an FSGS phase 2 clinical trial, and formalisation of a development plan for diabetic nephropathy.

The Entitlements are non-renounceable and will not be tradable on ASX or otherwise transferable. Shareholders who do not take up their Entitlements will not receive any value for those

Entitlements that they do not take up. Shareholders who are not eligible to receive Entitlements will not receive any value for the Entitlements they would have received had they been eligible.

Existing option holders need to exercise their options and be registered retail holders of fully paid ordinary shares on the Record Date if they wish to participate in the Entitlement Offer.

It is expected that approximately 46,040,880 New Shares will be issued as part of the Entitlement Offer. New Shares issued under the Entitlement Offer will rank equally with existing shares.

Eligible shareholders may apply for some or all of their Entitlement under the Rights Issue, and may also apply for Additional New Shares in excess of their Entitlement. There is no maximum cap on the number of Additional New Shares for which an Eligible Shareholder may apply for, subject to there being a sufficient Shortfall under the Shortfall Offer.

Dimerix will notify shareholders as to whether they are eligible to participate in the Entitlement Offer. Eligible shareholders will be sent, on Wednesday, 13 December 2017, an information booklet including a personalised entitlement and acceptance form which will provide further details of how to participate in the Entitlement Offer. A copy of the Information Booklet will also be lodged with the ASX on 6 December 2017.

Dimerix confirms that no dividend or distribution has been, or is planning to be, announced.

Proposed timetable

Dimerix expects that the Entitlement Offer will be conducted according to the following timetable:

Event	Date
Announcement of Rights Issue, Appendix 3B, Cleansing Notice and Offer Document	Wednesday 6 December 2017
Notice Sent to Security Holders	Thursday 7 December 2017
Ex Date (date from which securities commence trading without the entitlement to participate in the Offer)	Friday 8 December 2017
Record Date (date for determining entitlements of eligible shareholders to participate in the Offer as at 7:00pm (AEDT))	Monday 11 December 2017
Offer Document Dispatched to Shareholders (expected date of dispatch of offer document, entitlement and acceptance forms)	Wednesday 13 December 2017
Rights Issue Opens	Wednesday 13 December 2017
Closing Date* 7:00pm (AEDT)	Friday 19 January 2018
New Shares quoted on a deferred settlement basis	Monday 22 January 2018
ASX Notified of Shortfall and Underwriting	Wednesday 24 January 2018
Issue Date**	Thursday 25 January 2018
Dispatch Holding Statements**	Thursday 25 January 2018

** This timetable is indicative only. The directors may vary these dates subject to the ASX Listing Rules. An extension of the closing date will delay the anticipated date for issue of the New Shares. The directors of Dimerix also reserve the right not to proceed with the whole or part of the Entitlement Offer any time prior to the issue of the New Shares under the Entitlement Offer. In that event, the relevant application monies (without interest) will be returned in full to applicants.*

For more information, please contact the Company Secretary on +61 8 9388 8290.

Signed for and on behalf of Dimerix Limited



Ian Hobson
Company Secretary
Dimerix Limited